Thomson reuters report

Thomson Reuters press-release: World Generic Medicines Congress Europe

The World Generic Medicines Congress Europe organized by Health Network Communications brought together industry stakeholders, decision makers, and experts for two days of presentations and discussions focused on market challenges and portfolio strategy. The industry has seen a collapse of traditional commodity generic models, while a new model is emerging from innovation and consolidation, supported by strategic geographic expansion. The …

Eatern Europe, CIS, Generics

Back to the future

At the World Generic Medicines Congress Europe 2014, Stephen Stead, Ranbaxy, gave the presentation: “Back to the future” discussing the pharma industry. Download and learn: Volatility Diversity Russia Pharma market size and its dynamic Split of Innovator & Generics CAR Countries Ukrainian Pharma Environment Main market segments dynamics Cost containment and Volatility not Sustainability Download presentation  Found this interesting? Join us at …

Hikma, Pharma, Generics

Review of market dynamics in MENA: What are the market drivers, opportunities and challenges?

At the World Generic Medicines Congress Europe 2014, Salah Mawajdeh, Hikma Pharmaceuticals, gave a presentation on “Review of market dynamics in MENA: What are the market drivers, opportunities and challenges?”  The presentation focuses on healthcare and growth within the MENA region. Download and learn: The pharmaceutical industry in MENA High barriers to entry in the MENA & Hikma’s differentiated market position …

IP, Pharma, Generics, Opportunities, Challenges, Europe,

IP in Pharma Generics Opportunities & Challenges in the EU

At the World Generic Medicines Congress Europe 2014, Thomas Kolzau, Helm AG, gave a presentation entitled “IP in Pharma Generics Opportunities & Challenges in the EU” Download and learn: Opportunities – pharma generics Challenges – pharma generics Oppositions in the generic market Appeals in the generic market Settlement Manufacturing & stockpiling Importance of the EU generics industry Impact of a manufacturing …

Download ebook: Your Patent Expiry Update – 2014 and beyond

Patent expiry has increasingly proved problematic for the Pharma industry. Whilst blockbuster drugs lose their patent protection and companies suffer losses in brand spending, generics steal the market with cheap, accessible, copycat alternatives.  While products worth $66 billion will lose protection in 2015, companies grasp on to their patents insisting they promise innovation and aid invention. The debate over the …

Europe, US, Transatlantic, Trade, Investment, Agreement, Generics

EU-US Transatlantic Trade and Investment Agreement (TTIP) Impact on the Generics Industry

At the World Generic Medicines Congress Europe 2014, Michel Mikail, Fresenius Kabi, gave a presentation on “EU-US Transatlantic Trade and Investment Agreement (TTIP) Impact on the Generics Industry”. Download and learn: EU-US Transatlantic Trade & Investment Partnership (TTIP) Intellectual Property Rights Other ongoing negotiations FTAs’ opportunities and challenges Download presentation  Found this interesting? Join us at the 9th annual World Generic Medicines Congress Europe, …

competitive, generics, market

Small is beautiful: Winning in the highly competitive generics market

At the World Generic Medicines Congress Europe 2014, John Beighton, CEO,  Amdipharm Mercury Company Ltd gave a presentation on “Small is beautiful: Winning in the highly competitive generics market” Beighton’s presentation explores an entrepreneur’s dilemma of “How to grow without losing the “spirit” of what creates value” Download and learn: Strategic Growth Background: The In-market value chain Global Coverage Five Distinct go-to-market approaches for …

GaBi Journal partners with Total Biopharma, in association with the World Biosimilar Congress, Nov 2014

Guest Post: GaBI – Building trust in cost-effective treatments

A frequent partner of our Life Science conferences, GaBI Journal is an independent and peer reviewed academic journal, encompassing all aspects of generic and biosimilar medicines development and use, from fundamental research up to clinical application and policies. View the latest issue of GaBI Journal to learn about pharmaceutical innovation and developments in generic and biosimilar medicines. Volume 3, 2014, Issue …

Dr Reddy’s launches antibiotic drug in US market

Dr Reddy’s Laboratories has launched Moxifloxacin Hydrochloride tablets in the US market for the treatment of diseases including pneumonia, bronchitis and skin infections. It was approved by the United States Food and Drug Administration, amidst the tightened regulations by the FDA on Indian exports. The tablets are a generic version of Avelox. Bayer’s Avelox is for the treatment of community …